Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension

Journal of Hypertension

Volumn 29, Issue 4, 2011, Pages 803-808

  Izzo, Raffaele ^a   De Simone, Giovanni ^a,b,c,d   Devereux, Richard B ^a   Giudice, Renata ^a   De Marco, Marina ^a,c   Cimmino, Claudia S ^a   Vasta, Antonio ^a   De Luca, Nicola ^a   Trimarco, Bruno ^a  

^a Cardiovascular and Immunological Sciences ^*  (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

control of blood pressure; hypertension; left ventricular mass

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 79952760463     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328343ce32     Document Type: Article

References (38)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206. (Pubitemid 37430058)
4. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hypertension. 4. The role of inheritance. Clin Sci (Lond) 1954; 13:273-304.
5. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hypertension. II. Scores for arterial blood pressures adjusted for differences in age and sex. Clin Sci (Lond) 1954; 13:37-49.
6. Hamilton M, Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hypertension. I. The arterial pressure in the general population. Clin Sci (Lond) 1954; 13:11-35.
7. Pickering GW, Roberts JA, Sowry GS. The aetiology of essential hypertension. 3. The effect of correcting for arm circumference on the growth rate of arterial pressure with age. Clin Sci (Lond) 1954; 13:267-271.
8. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:1514-1520. (Pubitemid 19177621)
9. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36:594-599.
10. Arcucci O, de Simone G, Izzo R, Rozza F, Chinali M, Rao MA, et al. Association of suboptimal blood pressure control with body size and metabolic abnormalities. J Hypertens 2007; 25:2296-2300. (Pubitemid 47537924)
11. Aijaz B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc 2008; 83:1350-1357.
12. Peterson LR. Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep 2006; 8:451-456. (Pubitemid 44842770)
13. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994; 23:600-606. (Pubitemid 24129354)
14. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991; 266:231-236.
15. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002; 20:323-331. (Pubitemid 34913799)
16. de Simone G, Devereux RB, RomanMJ, Schlussel Y, Alderman MH, Laragh JH. Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. Ann Intern Med 1991; 114:202-209.
17. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90:179-185. (Pubitemid 24203678)
18. de Simone G, Devereux RB, Chinali M, Roman MJ, Welty TK, Lee ET, et al. Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. J Hypertens 2008; 26:1868-1874.
19. De Marco M, de Simone G, Roman MJ, Chinali M, Lee ET, Russell M, et al. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. Hypertension 2009; 54:974-980.
20. De Luca NA, Izzo RA, Iaccarino GA, Malini PLB, Morisco CA, Rozza FA, et al. The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens 2005; 23:1417-1423.
21. Izzo R, de Simone G, Chinali M, Iaccarino G, Trimarco V, Rozza F, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009; 32:845-850.
22. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-1197.
23. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998; 68:899-917.
24. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483. (Pubitemid 43855050)
25. Stergiopulos N, Meister JJ, Westerhof N. Simple and accurate way for estimating total and segmental arterial compliance: the pulse pressure method. Ann Biomed Eng 1994; 22:392-397. (Pubitemid 24264086)
26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463. (Pubitemid 41821197)
27. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458. (Pubitemid 16119719)
28. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-1260.
29. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
30. Graves JW, Sheps SG. Does evidence-based medicine suggest that physicians should not be measuring blood pressure in the hypertensive patient? Am J Hypertens 2004; 17:354-360. (Pubitemid 38446851)
31. Cuspidi C, Lonati L, Sampieri L, Macca G, Michev I, Salerno M, et al. Impact of blood pressure control on prevalence of left ventricular hypertrophy in treated hypertensive patients. Cardiology 2000; 93:149-154.
32. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension 2002; 39:744-749. (Pubitemid 34252868)
33. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
34. Dustan HP, Tarazi RC. Cardiogenic hypertension. Annu Rev Med 1978; 29:485-493.
35. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100:525-534.
36. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462. (Pubitemid 39238023)
37. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens 1998; 11 (11 Pt 1):1394-1404. (Pubitemid 28541059)
38. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46. (Pubitemid 36831120)